Ser36
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser36  -  LYL1 (human)

Site Information
APPPKPAsPGPPQVE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 15624701

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 5 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 ) , phospho-antibody ( 5 ) , western blotting ( 5 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 ) , leukemia ( 6 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 4 ) , acute megakaryoblastic leukemia (M7) ( 4 ) , acute monoblastic leukemia (M5a) or acute monocytic leukemia (M5b) ( 4 ) , acute myeloblastic leukemia, with granulocytic maturation (M2) ( 4 ) , acute myeloblastic leukemia, without maturation (M1) ( 4 ) , chronic myelogenous leukemia ( 6 ) , B cell lymphoma ( 4 ) , non-Hodgkin's lymphoma ( 4 ) , follicular lymphoma ( 2 ) , multiple myeloma ( 4 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Kinases, in vitro:
ERK1 (human) ( 5 ) , ERK2 (human) ( 5 )
Phosphatases, in vitro:
PPP1CA (human) ( 5 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Rolland D, et al. (2014) Global phosphoproteomic profiling reveals distinct signatures in B-cell non-Hodgkin lymphomas. Am J Pathol 184, 1331-42
24667141   Curated Info

3

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

4

Casado P, et al. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors. Genome Biol 14, R37
23628362   Curated Info

5

Lukov GL, Goodell MA (2010) LYL1 degradation by the proteasome is directed by a N-terminal PEST rich site in a phosphorylation-independent manner. PLoS One 5
20844761   Curated Info

6

Stokes M (2008) CST Curation Set: 4394; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info